<DOC>
	<DOCNO>NCT02947100</DOCNO>
	<brief_summary>The purpose study determine safety new formulation omega-3 fatty acid Docosahexaenoic Acid ( DHA ) Eicosapentaenoic Acid ( EPA ) ass whether decrease inflammation inflammatory pain child young adult Sickle Cell Disease .</brief_summary>
	<brief_title>Omega-3 Fatty Acids Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Subjects meet follow criterion eligible enrollment study : Participant sign inform consent/assent parent signing inform consent age appropriate . Established diagnosis HbSS , HbSC HbSβo Thalassemia History ≥1 vasoocclusive event ( manage home and/or hospital ) precede 12 month . Regular compliance comprehensive care . Aged 8 year great less 26 year . At enrollment , subject his/her baseline steady state midst acute complication due SCD . Must least 2 week infection vasoocclusive crisis time screen labs Baseline hemoglobin level &lt; 5.5 gm/dL . Inability swallow capsule Poor compliance previous treatment regimen . Hepatic dysfunction Renal dysfunction PT and/or PTT ≥ 20 % outside normal Allergy fish , shell fish soy Triglyceride level &lt; 80mg/dL . Pregnancy . Chronic Transfusion Therapy . Transfusion within last 30 day . Treatment investigational drug regular fish oil supplementation last 60 day . Currently receive another investigational agent , agent last 60 day . Dosage change precede 3 month hydroxyurea Diagnosed bleed disorder patient concomitant anticoagulation . Conditional abnormal result recent transcranial doppler history stroke . Other active chronic illness could adversely affect subject performance Children Care</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>Docosahexaenoic Acid ( DHA )</keyword>
	<keyword>Eicosapentaenoic Acid ( EPA )</keyword>
</DOC>